Renal Cancer - Results from #1180

Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib. January 12, 2023

Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination therapy. January 12, 2023

Role of tumor-derived exosomes in metastasis, drug resistance and diagnosis of clear cell renal cell carcinoma. January 11, 2023

Neutrophil extracellular traps-associated modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of clear cell renal cell carcinoma. January 11, 2023

Proteomics Characterization of Clear Cell Renal Cell Carcinoma. January 10, 2023

Patient Factors Impacting Perioperative Outcomes for T1b-T2 Localized Renal Cell Carcinoma May Guide Decision for Partial versus Radical Nephrectomy. January 10, 2023

Local Treatment of Recurrent Renal Cell Carcinoma May Have a Significant Survival Effect Across All Risk-of-recurrence Groups. January 9, 2023

Percutaneous cryoablation versus partial nephrectomy for cT1b renal tumors: An inverse probability weight analysis. January 9, 2023

Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective. January 6, 2023

Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma. January 6, 2023

The State of Robotic Partial Nephrectomy: Operative, Functional, and Oncological Outcomes from A Robust Multi-Institution Collaborative. January 5, 2023

Targeting hyaluronic acid synthase-3 (HAS3) for the treatment of advanced renal cell carcinoma. January 5, 2023

Tumor biology, biomarkers, and liquid biopsy in pediatric renal tumors. January 4, 2023

Association of Volatile Versus Intravenous Anesthesia With Prognosis After Nephrectomy for Renal Cell Carcinoma. January 4, 2023

Age-Related Differences in Oncological Outcomes in Renal Cell Carcinoma: Impact of Functional Conservation as Measured by Postoperative eGFR. January 3, 2023

Semantic computed tomography features for predicting BRCA1-associated protein 1 and/or tumor protein p53 gene mutation status in clear cell renal cell carcinoma. January 3, 2023

Nomograms for predicting overall and cancer-specific survival of patients with chromophobe renal cell carcinoma after nephrectomy: a retrospective SEER-based study. January 2, 2023

No difference in renal function outcomes for patients with oncocytoma managed with active surveillance vs. partial nephrectomy. January 2, 2023

Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial. December 30, 2022

Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3. December 30, 2022

Page 60 of 458